Skip to content
DataLookout
Menu

NCT02051218

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 50 versions: 41 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication Show 4 more changesShow less
    • Eligibility criteria expanded, about 24 words
    • Primary completion date changed from estimate of Jun 30, 2026 to Mar 20, 2026
    • Site details revised at 9 of 50 sites
    • Publications: details revised at 1 of 1 entry
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 50 of 50 sites
    v46
  3. Minor Study sites revised (50)v45
  4. Minor Site details revised at 1 of 50 sitesv44
  5. Minor Site contacts updated at 1 of 50 sitesv42
Show 35 earlier versionsHide 35 earlier versions
  1. Notable Primary completion date: Dec 2022 to Jun 30, 2026
    • Study completion date: Dec 2022 to Dec 31, 2028
    • Study sites revised (50)
    v41
  2. Minor Site contacts updated at 2 of 50 sitesv40
  3. Minor Site contacts updated at 1 of 50 sitesv39
  4. Minor Study sites revised (50)v38
  5. Notable Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Dec 2021 to Dec 2022
    • Enrollment target: 1181 to 1380
    • Site details revised at 50 of 50 sites
    v36
  6. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 1380 to confirmed 1181
    • Site details revised at 50 of 50 sites
    v33
  7. Minor Site contacts updated at 2 of 50 sitesv32
  8. Minor Site contacts updated at 1 of 50 sitesv31
  9. Minor Site contacts updated at 1 of 50 sitesv30
  10. Notable Primary completion date: Dec 2019 to Dec 2021v29
  11. Minor Study sites: 49 to 50v27
  12. Minor Site details revised at 2 of 49 sitesv26
  13. Minor Study sites: 48 to 49v25
  14. Minor Study sites: 47 to 48v24
  15. Minor Site contacts updated at 1 of 47 sitesv23
  16. Minor Site contacts updated at 1 of 47 sitesv22
  17. Minor Study sites: 46 to 47v21
  18. Minor Site contacts updated at 1 of 46 sitesv20
  19. Minor Study sites: 45 to 46v19
  20. Minor Study sites: 40 to 45
    • Secondary endpoints revised (8)
    v18
  21. Minor Study sites: 39 to 40v17
  22. Minor Study sites revised (39)v16
  23. Minor Study sites: 32 to 39
    • Start date: Jul 2014 to Jul 16, 2014
    v15
  24. Minor Site contacts updated at 1 of 32 sitesv14
  25. Minor Site details revised at 6 of 32 sitesv13
  26. Minor Study sites: 30 to 32v12
  27. Minor Study sites: 29 to 30v11
  28. Minor Site details revised at 1 of 29 sitesv10
  29. Minor Study sites: 28 to 29v9
  30. Minor Site contacts updated at 1 of 28 sitesv8
  31. Minor Site contacts updated at 1 of 28 sitesv6
  32. Minor Study sites: 26 to 28v5
  33. Notable Eligibility criteria expanded, about 28 words
    • Secondary endpoints revised (8)
    v4
  34. Minor Study sites: 7 to 26v3
  35. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2014 to Jul 2014
    • Study sites: 3 to 7
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression).
Timeframe: at the latest 5 years after randomization.

Secondary (8)

Toxicity (focus on hypocalcaemia and osteonecrosis of the jaw)
Time to first and subsequent on-trial SSE
Quality of Life measured by FACT-G and FACT-BP
Skeletal morbidity period rate (SMPR)
Skeletal morbidity rate (SMR)
Show 3 moreShow less
Health economic analysis
Bone turnover markers
Overall Survival (OS)

Arms and interventions

Arm A (standard arm)Active comparator

Denosumab 120mg (XGEVA®) sc. q4w

Arm B (reduced arm)Experimental

Denosumab 120mg (XGEVA®) sc. q4w \[weeks 1, 5, 9\] followed by Denosumab 120mg (XGEVA®) sc. q12w \[weeks 13, 25, …\]

Drugs: Denosumab (reduced dosing), Denosumab (standard dosing)

Sites

50 sites in 3 countries

Switzerland 43, Germany 5, Austria 2